BPC-157 (Cognitive)

Also known as: BPC-157 neuroprotective protocol

CognitivePRECLINICAL

Clinical Status

Preclinical — cognitive applications based on dopaminergic system research.

Mechanism of Action

BPC-157 interacts with the dopaminergic system, modulates serotonin and GABA pathways, and promotes nerve regeneration. Research shows neuroprotective effects and potential to restore dopamine system function after damage.

Dosing Defaults

Dose

250-500 mcg

Frequency

2x daily

Administration

Subcutaneous injection or intranasal

Timing

Morning and evening

Food

with or without

Duration

4-8 weeks

Dose range: 200-1,000 mcg per day

Split dosing maintains neuroprotective levels throughout the day.

Side Effects

•Nausea
•Dizziness
•Injection site reactions
•Fatigue
•Headache

Contraindications & Warnings

⚠Active cancer

•Not medical advice
•Same compound as healing BPC-157 — cognitive application is off-label
•FDA Category 2

Compare

Compare BPC-157 (Cognitive) with another peptide side-by-side.

Calculate Dose

Use the reconstitution calculator to prepare your BPC-157 (Cognitive) dose.

Open Calculator

Related Cognitive Peptides

Selank

PHASE 2

Cognitive

Anxiolytic peptide approved in Russia. Non-sedative, non-addictive.

Semax

PHASE 2

Cognitive

Nootropic peptide approved in Russia. Enhances focus, memory, and neuroplasticity.

Dihexa

PRECLINICAL

Cognitive

Potent nootropic that promotes synapse formation. No human trials.

Noopept

PHASE 2

Cognitive

Dipeptide-derived nootropic for memory and neuroprotection. Approved in Russia.

This information is for educational purposes only and is not medical advice. Dosing data is based on research literature and community reports. Always consult a qualified healthcare provider before using any peptide.